Michael Christini, J.D., CEO  

Michael has more than 20 years of operations, IP, legal and transactional experience in the biotech industry. Michael previously founded and led Nurel Therapeutics until its sale to Diamyd (Stockholm) and Catherex until its sale to Amgen. He has previously also held positions as a biotech transactional attorney at Cooley Godward, the Federal Trade Commission, and the National Cancer Institute. 

G. Yancey Gillespie, Ph.D.,  CSO  

Yancey is Professor Emeritus of Neurosurgery at the University of Alabama Birmingham (UAB) with over 27 years direct research experience with oncolytic HSV and G207. Yancey was instrumental in developing the protocols for the three previous G207 adult brain tumor trials. He is a Scientific Advisory Board Member for the American Brain Tumor Association, the Pediatric Brain Tumor Foundation, and the National Brain Tumor Society (Chair) and the National Brain Tumor Society (Chair).  Previously he co-directed the Neuro Oncology Program in the UAB O'Neal Comprehensive Cancer Center.  


Other Treovir Advisors

James Markert, MD, is Chairman of Neurosurgery, UAB.  Clinical oncolytics expert.  Dr. Markert served as PI on all three G207 adult glioblastoma trials and other oncolytic virus glioma studies. 

Richard Whitley, MD, is Chief, Pediatric Infectious Diseases, Children’s of Alabama.  Dr. Whitley has more than 30 years research experience with oncolytic viruses, oncolytic HSV and G207.  He is also a Board Member for Gilead Sciences.